Hexagon Bio is a data-driven biotech company developing targeted small molecule therapeutics.
Hexagon Bio has raised $77.3M in total funding. The most recent round was Series B. The last funding was announced in October 2022.
Hexagon Bio's investors include 8VC, The Column Group, Casdin Capital, SoftBank Vision Fund, Two Sigma Ventures.
Hexagon Bio is headquartered in Menlo Park, United States.
Hexagon Bio is a data-driven biotech company developing targeted small molecule therapeutics.
Hexagon Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Hexagon Bio — Funding & Investors." VCBacked, October 11, 2022, https://www.vcbacked.co/company/hexagon-bio. Accessed July 19, 2026.
VCBacked. (2022). Hexagon Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/hexagon-bio
{{cite web |title=Hexagon Bio — Funding & Investors |url=https://www.vcbacked.co/company/hexagon-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated